Science Education
>

An In Vitro Approach to Study Mitochondrial Dysfunction: A Cybrid Model

LEHRERVORBEREITUNG
KONZEPTE
SCHÜLERPROTOKOLL
JoVE Journal
Genetik
Zum Anzeigen dieser Inhalte ist ein JoVE-Abonnement erforderlich.  Melden Sie sich an oder starten Sie Ihre kostenlose Testversion.
JoVE Journal Genetik
An In Vitro Approach to Study Mitochondrial Dysfunction: A Cybrid Model

NOTE: The use of human fibroblasts may require ethical approval. Fibroblasts used in this study were derived from MD patients and stored in the Institutional biobank in compliance with ethical requirements. Informed consent was provided for the use of the cells. Perform all cell culture procedures under a sterile laminar flow cabinet at room temperature (RT, 22-25 °C). Use sterile-filtered solutions suitable for cell culture and sterile equipment. Grow all cell lines in a humidified incubator at 37 °C with 5% CO2. Mycoplasma tests should be conducted weekly to ensure mycoplasma-free cultures. 143BTK rho0 cells can be generated as previously described5.

1. Culture of cells

  1. Before starting any procedure, verify the presence of the mutation in fibroblasts derived from MD patient(s) and quantify the percentage of heteroplasmy or homoplasmy by Restriction Fragment Length Polymorphism (RFLP) and/or whole mtDNA sequencing analyses14.
  2. Seed fibroblasts in four 35 mm Petri dishes, each containing 2 mL of Complete Culture Medium (Table 1). Let the cells grow until 80% confluent (48 h).
  3. Grow 143BTK rho0 cells in 8 mL of Supplemented Culture Medium (Table 1) in a 100 mm Petri dish.
  4. Maintain the cells in an incubator at 37 °C with 5% CO2.
  5. Check the absence of mtDNA in rho0 cells by sequencing techniques14.

2. Enucleation of fibroblasts

  1. Sterilize four 250 mL centrifuge-suitable bottles by autoclave sterilization at 121 °C for a 20 min cycle. Dry them in a laboratory oven or at RT.
  2. Prewarm the centrifuge at 37 °C.
  3. Wash the 35 mm dishes containing the fibroblasts twice, using 2 mL of 1x phosphate-buffered saline (PBS) without (w/o) calcium and magnesium.
  4. Clean the outer surface of the dishes with 70% ethanol and wait until the alcohol evaporates.
  5. Remove the lids from the dishes and the screw caps from the bottles. Place each dish, without the lid, upside down on the bottom of each 250 mL centrifuge bottle.
  6. Slowly add 32 mL of Enucleation Medium to each bottle (Table 1), allowing the medium to enter the dish and come into contact with the cells. Remove any bubbles from the dishes using a long glass Pasteur pipette, curving the tip in a Bunsen flame.
    NOTE: It is important to remove the bubbles to allow the medium to enter the dish and come in contact with the cells.
  7. Close each bottle with the screw cap and transfer them to the centrifuge.
  8. Centrifuge for 20 min at 37 °C and 8,000 × g, acceleration max, deceleration slow. Pay attention to balance the centrifuge: counterweight each bottle. If necessary, adjust the weight by adding a suitable volume of Enucleation Medium.
  9. During centrifugation, use vacuum or a 10 mL serological pipette to aspirate and discard the medium from the 143BTK rho0 culture plates and wash them twice using 4 mL of 1x PBS w/o calcium and magnesium.
  10. Add 2 mL of trypsin to cover the cell monolayer completely.
  11. Place the dishes in a 37 °C incubator for ~2 min.
  12. Remove the dishes from the incubator, observe cell detachment using an inverted microscope for live cells (objectives 4x or 10x), and inhibit the enzyme activity by adding 2 mL of Supplemented Culture Medium.
  13. Aspirate the 4 mL of the cell suspension in the dish with a 10 mL pipette and transfer it to a 15 mL conical tube.
  14. Count the cells using a Burker hemocytometer chamber or an automated counter.
  15. At the end of centrifugation (step 2.8), aspirate the medium from the bottles and discard it.
  16. Remove the dishes by inverting the bottles on a sterile gauze previously sprayed with 70% ethanol. Clean the outer surface of the dishes and their lids with 70% ethanol. Wait until the alcohol evaporates, and then close the dishes.
  17. Before proceeding, check for cytoplast (ghost) formation using an inverted microscope for live cells (objective 4x or 10x). Look for extremely elongated fibroblasts due to the extrusion of their nuclei induced by cytochalasin B.
  18. To each 35 mm dish, add 1 × 106 of 143BTK rho0 cells resuspended in 2 mL of 143BTK rho0 culture medium supplemented with 5% fetal bovine serum (FBS).
  19. Leave the dishes for 3 h in a humidified incubator at 37 °C and 5% CO2 and let the 143BTK rho0 cells settle on the ghosts. Do not disturb the dishes.

3. Fusion of the enucleated fibroblasts with rho 0 cells

  1. After 3 h of incubation, aspirate and discard the medium from the dishes.
  2. Wash the adherent cells twice with 2 mL of Dulbecco's Modified Eagle Medium (DMEM) high glucose w/o serum or with Minimum Essential Medium (MEM).
  3. Aspirate and discard the medium.
  4. Add 500 µL of PEG solution (see the Table of Materials) to the cells and incubate for exactly 1 min.
  5. Aspirate and discard the PEG solution.
  6. Wash the cells three times using 2 mL of DMEM high glucose w/o serum or with MEM.
  7. Add 2 mL of Fusion Medium (Table 1) and incubate overnight in the incubator at 37 °C with 5% CO2.

4. Cybrid selection and expansion

  1. After overnight incubation, remove the plates from the incubator, trypsinize the cells as described above (steps 2.9-2.13), and transfer the content of each 35 mm dish into a 100 mm dish.
  2. Add 8 mL of Selection Medium (Table 1) and place the plates in the incubator at 37 °C with 5% CO2.
  3. Change the medium every 2-3 days.
  4. Wait for ~10-15 days of selection until colonies of cells appear.
  5. Freeze one of the four Petri dishes by collecting all the clones and generating a "massive" culture as a backup of the cybrids, which can be eventually recloned and used for further investigations.
  6. Trypsinize the cells in the remaining culture dishes, count, and seed into one or more Petri dishes at 50-100 cells/dish in the Supplemented Culture Medium (Table 1) until clones appear. Let them grow for some days.
  7. Pellet the remaining cells by centrifugation at 1,200 × g for 3 min at RT and discard the supernatant.
  8. Extract DNA from the pellet (see the Table of Materials).
  9. Perform genotyping by variable number of tandemly repeated (VNTR) analysis as previously reported15.
  10. Pick up clones from the Petri dish with cloning cylinders or a pipette tip, using a stereomicroscope to avoid pooling of different clones, and transfer them to a 96-well plate, each well containing 200 µL of Supplemented Culture Medium (Table 1).
  11. Expand every clone until there are enough cells for freezing and extracting DNA.
  12. Verify the mutation percentage of each clone by RFLP or other sequencing methods. Ideally, try to obtain both clones with wild-type mtDNA (0% mutation) and clones with different mutation percentages, both adding up to homoplasmic mutant mtDNA (100% mutation). See Figure 1 for a schematic diagram of the cybrid generation protocol.

An In Vitro Approach to Study Mitochondrial Dysfunction: A Cybrid Model

Learning Objectives

Generating cybrids requires 3 days of laboratory work plus a selection period (~2 weeks) and additional 1-2 weeks for the growth of clones. The critical steps are the quality of cytoplasts and the selection period. The morphology of cybrids resembles that of the rho0 donor cells. Assignment of the correct mtDNA and nDNA in the cybrids is mandatory to confirm the identity of the cells. An example is given in Figure 2. In this case, we generated cybrids starting from fibroblasts derived from a patient carrying the heteroplasmic m.3243A>G, one of the most common mtDNA mutations associated with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS). Analysis of VNTR showed that cybrid nDNA is identical to that of the rho0 cells (Figure 2A), confirming the replacement of the patient's nDNA with the 143B genome. RFLP and/or sequencing analyses can be used to assess the presence of the mtDNA mutation and the heteroplasmy percentage (Figure 2B,C).

Figure 1
Figure 1: Schematic diagram of the cybrid generation protocol. Patient-derived fibroblasts are treated with cytochalasin B and centrifuged to obtain cytoplasts (enucleated cells). Cytoplasmic fusion of cytoplasts and mtDNA-depleted cells (143BTk rho0) allows the generation of cybrids that can be isolated after selection in the appropriate medium. Picking up and amplification of single clones yields different heteroplasmy percentages, which in theory can vary from 100% wild-type to 100% mutated. Abbreviation: mtDNA = mitochondrial DNA. Please click here to view a larger version of this figure.

Figure 2
Figure 2: Molecular characterization of cybrids. (A) Analysis of Apo-B microsatellites shows that the nDNA extracted from the generated cybrids is identical to the nuclear DNA of the rho0 cell line. (B) HaeIII restriction maps of the PCR product spanning the MELAS-associated m.3243A>G, used to quantify the amount of WT) and Mut mtDNA species. (C) Representative results of RFLP analysis showing m.3243A>G heteroplasmy levels in different cybrid clones (c1, c2, c3). Abbreviations: M = marker; bp = base pairs; WT = wild-type; Mut = mutant; RFLP = restriction fragment length polymorphism; MELAS = mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes. Please click here to view a larger version of this figure.

Media Composition
Complete culture medium Final conc.
DMEM High Glucose (w/o L-Glutamine W/Sodium Pyruvate) [1:1]
FetalClone III (Bovine Serum Product) 10%
Sodium Pyruvate 100 mM 1 mM
Penicillin-Streptomycin (solution 100x) 1%
L-Glutamine 200 mM (100x) 2 mM
Supplemented culture medium Final conc.
DMEM High Glucose (w/o L-Glutamine W/Sodium Pyruvate) [1:1]
FetalClone III (Bovine Serum Product) 10%
Sodium Pyruvate 100 mM 1 mM
Penicillin-Streptomycin (solution 100x) 1%
L-Glutamine 200 mM (100x) 4 mM
Uridine 50 µg/mL
Enucleation medium Final conc.
DMEM High Glucose (w/o L-Glutamine W/Sodium Pyruvate) [1:1]
FetalClone III (Bovine Serum Product) 5%
Sodium Pyruvate 100 mM 1 mM
Penicillin-Streptomycin (solution 100x) 1%
L-Glutamine 200 mM (100x) 2 mM
Cytochalasin B from Drechslera dematioidea 10 µg/mL
Fusion medium Final conc.
DMEM High Glucose (w/o L-Glutamine W/Sodium Pyruvate) [1:1]
FetalClone III (Bovine Serum Product) 5%
Sodium Pyruvate 100 mM 1 mM
Penicillin-Streptomycin (solution 100x) 1%
L-Glutamine 200 mM (100x) 2 mM
Selection medium Final conc.
DMEM High Glucose (w/o L-Glutamine W/Sodium Pyruvate) [1:1]
Dialyzed FBS 5%
Sodium Pyruvate 100 mM 1 mM
Penicillin-Streptomycin (solution 100x) 1%
L-Glutamine 200 mM (100x) 2 mM
5-Bromo-2'-Deoxyuridine 100 µg/mL

Table 1: Details of media used for cybrid generation.

List of Materials

5-Bromo-2'-Deoxyuridine Sigma-Aldrich (Merck) B5002-500MG
6 well Plates Corning 3516
96 well Plates Corning 3596
Blood and Cell Culture DNA extraction kit QIAGEN 13323
Centrifuge Beckman Coulter Avanti J-25 7,200 rcf, 37 °C
Centrifuge bottles, 250 mL Beckman Coulter 356011
Cytochalasin B from Drechslera dematioidea Sigma-Aldrich (Merck) C2743-200UL
Dialyzed FBS Gibco 26400-036 100mL
DMEM High Glucose (w/o L-Glutamine W/Sodium Pyruvate) EuroClone ECB7501L
Dulbecco's Phosphate Buffered Saline – PBS (w/o Calcium w/o Magnesium) EuroClone ECB4004L
Ethanol Absolute Anhydrous Carlo Erba 414601
FetalClone III (Bovine Serum Product) Cytiva – HyClone Laboratories SH30109.03
Glass pasteur pipettes VWR M4150NO250SP4
Inverted Research Microscope For Live Cell Microscopy Nikon ECLIPSE TE200
JA-14 Fixed-Angle Aluminum Rotor Beckman Coulter 339247
Laboratory autoclave Vapormatic 770 Labotech 29960014
L-Glutamine 200 mM (100x) EuroClone ECB 3000D
Minimum Essential Medium MEM Euroclone ECB2071L
MycoAlert Mycoplasma Detection Kit Lonza LT07-318
PEG (Polyethylene glicol solution) Sigma-Aldrich (Merck) P7181-5X5ML
Penicillin-Streptomycin (solution 100x) EuroClone ECB3001D
Primo TC Dishes 100 mm EuroClone ET2100
Primo TC Dishes 35 mm EuroClone ET2035
Sodium Pyruvate 100 mM EuroClone ECM0542D
Stereomicroscope Nikon SMZ1000
Trypsin 2.5% in HBSS EuroClone ECB3051D
Uridine Sigma-Aldrich (Merck) U3003-5G

Lab Prep

Deficiency of the mitochondrial respiratory chain complexes that carry out oxidative phosphorylation (OXPHOS) is the biochemical marker of human mitochondrial disorders. From a genetic point of view, the OXPHOS represents a unique example because it results from the complementation of two distinct genetic systems: nuclear DNA (nDNA) and mitochondrial DNA (mtDNA). Therefore, OXPHOS defects can be due to mutations affecting nuclear and mitochondrial encoded genes.

The groundbreaking work by King and Attardi, published in 1989, showed that human cell lines depleted of mtDNA (named rho0) could be repopulated by exogenous mitochondria to obtain the so-called "transmitochondrial cybrids." Thanks to these cybrids containing mitochondria derived from patients with mitochondrial disorders (MDs) and nuclei from rho0 cells, it is possible to verify whether a defect is mtDNA- or nDNA-related. These cybrids are also a powerful tool to validate the pathogenicity of a mutation and study its impact at a biochemical level. This paper presents a detailed protocol describing cybrid generation, selection, and characterization.

Deficiency of the mitochondrial respiratory chain complexes that carry out oxidative phosphorylation (OXPHOS) is the biochemical marker of human mitochondrial disorders. From a genetic point of view, the OXPHOS represents a unique example because it results from the complementation of two distinct genetic systems: nuclear DNA (nDNA) and mitochondrial DNA (mtDNA). Therefore, OXPHOS defects can be due to mutations affecting nuclear and mitochondrial encoded genes.

The groundbreaking work by King and Attardi, published in 1989, showed that human cell lines depleted of mtDNA (named rho0) could be repopulated by exogenous mitochondria to obtain the so-called "transmitochondrial cybrids." Thanks to these cybrids containing mitochondria derived from patients with mitochondrial disorders (MDs) and nuclei from rho0 cells, it is possible to verify whether a defect is mtDNA- or nDNA-related. These cybrids are also a powerful tool to validate the pathogenicity of a mutation and study its impact at a biochemical level. This paper presents a detailed protocol describing cybrid generation, selection, and characterization.

Verfahren

Deficiency of the mitochondrial respiratory chain complexes that carry out oxidative phosphorylation (OXPHOS) is the biochemical marker of human mitochondrial disorders. From a genetic point of view, the OXPHOS represents a unique example because it results from the complementation of two distinct genetic systems: nuclear DNA (nDNA) and mitochondrial DNA (mtDNA). Therefore, OXPHOS defects can be due to mutations affecting nuclear and mitochondrial encoded genes.

The groundbreaking work by King and Attardi, published in 1989, showed that human cell lines depleted of mtDNA (named rho0) could be repopulated by exogenous mitochondria to obtain the so-called "transmitochondrial cybrids." Thanks to these cybrids containing mitochondria derived from patients with mitochondrial disorders (MDs) and nuclei from rho0 cells, it is possible to verify whether a defect is mtDNA- or nDNA-related. These cybrids are also a powerful tool to validate the pathogenicity of a mutation and study its impact at a biochemical level. This paper presents a detailed protocol describing cybrid generation, selection, and characterization.

Tags